Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in pulmonary arterial hypertension
IRCT20200209046427N2Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of dapagliflozin in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Pro-BNP. Started Sep 2023; status: completed.
02
Drugs
dapagliflozin
03
Conditions
pulmonary arterial hypertension (PAH)chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on IRCT20200209046427N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200209046427N2.